Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

Inclusion Criteria: * Outpatients with symptomatic laboratory-proven diagnosis of COVID-19 (any exam that shows acute infection as positive PCR or IgM in a context of acute symptoms ≤ 10 days) AND * Negative pregnancy test for women in child bearing period AND * D-dimer level ≥ 2x ULN or * C-reactive protein (CRP) ≥ 10 mg/L or * At least two of the following risk factors: * d-dimer level ≥ULN * CRP ≥ULN * age ≥65, * diabetes, * chronic kidney disease stage 3 * cardiopulmonary disease (for example, peripheral arterial disease, coronary artery disease, heart failure, chronic obstructive pulmonary disease), * history of PE/DVT, * nursing home/SNF resident or severely restricted mobility * Body mass index ≥30 kg/m2. Exclusion Criteria: * Age \< 18 years-old * Patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis) * Platelets \< 50,000 /mm3 * Use of acetylsalicylic acid \> 100 mg per day * Use of P2Y12 inhibitor (clopidogrel, prasugrel, ticagrelor) * Chronic use of NSAIDs * Hypersensitivity to apixaban * Creatinine clearance \< 30 ml/min * Pregnancy or breastfeeding * Patients contraindicated to anticoagulation (active bleeding, recent major surgery, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator) * A history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (AV) malformation, or aneurysm * Use of strong inhibitors of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) (e.g. protease inhibitors, ketoconazole, Itraconazole) and/or use of P-gp and strong CYP3A4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's Wort)